Latest News
A new Irish financial services bill, which has been in the works for over five years, is expected to create 3,000 jobs by 2025, while attracting up to EUR20 billion per annum in global private capital, says Irish Funds.
Yellow Wood Partners, a Boston-based private equity firm focused on investing in consumer brands and companies, has promoted Jennifer Roach Pacini, Andrew Nguyen, and Sarah Mascioli Ensslen to Principal; Payton McVey to Vice President and; Amrutha Mandalap to Senior Associate.
Dana Schmaltz, Partner of Yellow Wood Partners, says: “We are excited to distinguish this group of talented professionals. They are indicative of the deep consumer talent within Yellow Wood. Through their diverse backgrounds and investment and operating experiences, they all have demonstrated the core values of our firm as we continue to build world-class consumer businesses.
“It is a great
Winston & Strawn has appointed Kathleen Blaszak, as a partner in the Corporate practice in the firm’s Washington DC.
Blaszak has extensive experience in the telecommunications, media and technology sectors, having represented media companies, private equity firms and entrepreneurs in the broadcast, cable, newspaper, digital media, technology and automotive sectors. She brings considerable experience advising these clients on mergers and acquisitions, new venture formations, joint ventures, complex commercial transactions, investments and strategic partnerships, and other general corporate and business matters.
“Winston has an outstanding reputation for quality and client service,” says Blaszak. “I am looking forward to working closely
The Kempen European Private Equity Fund has backed the senior management team at construction software company Eque2 to acquire the business from its existing shareholders.
Eque2 supplies business management software to more than 2,700 customers in the construction, housebuilding and contracting industries. Its software enables builders, contractors, architects, engineers and estimators to integrate the commercial and financial aspects of their business, driving efficiencies and ultimately improving profitability. Revenues have grown significantly over the last four years and it has proven to be exceptionally resilient during the Covid pandemic. The company continues to invest significantly in customer service and product development
ICV Partners, an investment firm focused on lower middle market companies in business services, consumer goods & services, food & beverage, and healthcare, announced today has made a majority investment in Total Access Urgent Care (TAUC), a provider of urgent care and many emergency department services in the Midwest, in partnership with the company’s management team.
Based in St Louis, Total Access Urgent Care operates 26 locations and serves patients in the Midwest region. Founded over 12 years ago by Dr Matt Bruckel, who today serves as Chief Executive Officer, TAUC is recognised for combining fast, friendly, and affordable healthcare
Evox Therapeutics (Evox), an exosome therapeutics company, has raised GBP69.2 million (USD95.4 million) in a Series C financing round.
The financing was significantly oversubscribed with high demand from both existing and new investors. The Series C financing was led by Redmile Group who were joined by new investors OrbiMed and Invus. In addition to Redmile, all existing Series B investors reinvested, including major investors Oxford Sciences Innovation (OSI), GV (formerly Google Ventures) and Cowen Healthcare Investments. Eli Lilly, also converted a USD10 million convertible note, that formed part of our 2020 collaboration agreement with them, into equity as part of
Eurazeo has sold part of its stake in iM Global Partner to IK Investment Partners and Luxempart, subject to the approval of the French Autorité des Marchés Financiers and the Commission de Surveillance du Secteur Financier.
This comes after iM Global Partner, a global network dedicated to asset management, increased its assets under management by 65 per cent – of which 46 per cent was organic growth – to more than USD19 billion in the year to end December 2020. With the support of Eurazeo and Amundi, which have supported Philippe Couvrecelle and the management team since the company’s inception,
Ally.io, a hypergrowth technology company specialising in goal-setting and business execution software, has closed a USD50 million (GBP36.5 million) Series C funding round led by Greenoaks Capital.
Tiger Global, which led the company’s Series B round, and Madrona Venture Group also joined the round, as well as previous investors Accel, Addition Ventures, Founders’ Co-Op, and Vulcan Capital.
With this funding, Ally.io has raised a total of USD76 million (GBP55.4 million), making the three-year-old SaaS company the leading force in the OKR space and primed to revolutionise how companies integrate goals with every business rhythm.
The news follows the
Agronomics, a London-listed investor in alternative proteins with a focus on cellular agriculture and cultivated meat, has invested a further EUR2 million for 1,197 Preferred shares in existing investee company Meatable.
The Subscription will be paid using cash from the Company’s own resources and will take Agronomics’ total cash investment in Meatable to EUR5 million.
Following the Subscription, Agronomics will hold 4,752 preferred shares in Meatable, representing an equity ownership, on a fully diluted basis, of 5.70 per cent. Subject to audit, Agronomics will now carry this position in its accounts at a book value of EUR7.95 million, representing
Advent Life Sciences has closed two new funds with commitments totalling USD215 million.
Advent Life Sciences Fund III is the firm’s third dedicated life sciences venture capital fund raised from new Limited Partners (LPs), including British Patient Capital, as well as existing LPs.
The Advent-Harrington Impact Fund is a new type of fund raised in collaboration with the Harrington Discovery Institute to translate innovative drug discoveries into novel treatments for the benefit of patients and society, otherwise known as ‘impact’ investing.
Investing at seed, series A and beyond, the funds will primarily support companies to develop new therapeutics but will
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
